Product
Larotrectinib
Aliases
ARRY 470 Sulfate, larotrectinib, Larotrectinib Sulfate, Larotrectinib (Vitrakvi, BAY2757556) (5 other aliases)
Name
Larotrectinib
Target
TRK
FDA Approved
Yes
Ema approved
Status
0
12 clinical trials
1 organization
1 drug
2 abstracts
52 indications
1 document
Indication
NTRK Fusion Positive Solid TumorsIndication
solid tumor with NTRK gene fusionIndication
Infantile FibrosarcomaIndication
Malignant NeoplasmIndication
Non-Hodgkin LymphomaIndication
Stage IV Non-Hodgkin LymphomaIndication
Histiocytic SarcomaIndication
Juvenile XanthogranulomaIndication
Langerhans Cell HistiocytosisIndication
Malignant GliomaIndication
Recurrent Childhood RhabdomyosarcomaIndication
EpendymomaIndication
Ewing SarcomaIndication
Recurrent GliomaIndication
HepatoblastomaIndication
Recurrent Langerhans Cell HistiocytosisIndication
Recurrent Malignant Germ Cell TumorIndication
Recurrent Malignant Solid NeoplasmIndication
MedulloblastomaIndication
NeuroblastomaIndication
OsteosarcomaIndication
Recurrent rhabdoid tumorIndication
Soft Tissue SarcomaIndication
GliomaIndication
Malignant Germ Cell TumorIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
Rhabdoid TumorIndication
RhabdomyosarcomaIndication
Soft Tissue Sarcoma AJCC v7Indication
Osteosarcoma AJCC v7Indication
Stage IV Soft Tissue Sarcoma AJCC v7Indication
Wilms tumorIndication
Wilms TumorIndication
Recurrent Malignant GliomaIndication
Refractory Soft Tissue SarcomaIndication
Metastatic Malignant Solid NeoplasmIndication
Central Nervous System NeoplasmIndication
Recurrent Acute LeukemiaIndication
Refractory Acute LeukemiaIndication
Solid TumorIndication
Thyroid CancerIndication
Pediatric CancerIndication
CancerIndication
ThyroidDrug
LarotrectinibIndication
salivary gland tumorsClinical trial
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK FusionStatus: Active (not recruiting), Estimated PCD: 2025-07-20
Clinical trial
Special Drug Use Investigation for LarotrectinibStatus: Recruiting, Estimated PCD: 2029-06-30
Clinical trial
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With LarotrectinibStatus: Recruiting, Estimated PCD: 2029-11-30
Clinical trial
A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-25
Clinical trial
A Comparison of Clinical Outcomes in Infantile Fibrosarcoma (IFS) Patients Treated With Larotrectinib in the Phase I/II SCOUT Study Versus (an) External Historical Cohort(s)Status: Completed, Estimated PCD: 2022-09-13
Clinical trial
Comparative Effectiveness Study of Real-world Control of TRK Fusion Positive Cancer With Patients From Larotrectinib (Vitrakvi) Clinical TrialsStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid TumorsStatus: Completed, Estimated PCD: 2017-02-01
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK FusionsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive TumorsStatus: Recruiting, Estimated PCD: 2025-11-11
Clinical trial
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute LeukemiasStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK FusionsStatus: Recruiting, Estimated PCD: 2024-10-01
Document
DailyMed Label: VITRAKVIOrganization
Bayer HealthCare Pharmaceuticals Inc.